A Study to Evaluate the Efficacy and Safety of AD-224

Phase 3CompletedNCT06291207

Addpharma Inc.254 enrolled

Overview

The purpose of this study is to evaluate the efficacy and safety of AD-224

Condition or disease : Essential Hypertension

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

254

Conditions

Hypertension,Essential

Interventions

AD-224ADRUG

PO, Once daily, 8weeks

AD-224BDRUG

PO, Once daily, 8weeks

AD-224CDRUG

PO, Once daily, 8weeks

Placebo of AD-224A

Eligibility

Sex: ALLMin age: 19 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Signed informed consent * Patients with Essential Hypertension * Other inclusions applied Exclusion Criteria: * Patient with Secondary Hypertension * Other exclusions applied

Locations (1)

Seoul National University Bundang Hospital

Seongnam-si, South Korea

Outcomes

Primary Outcomes

Change rate of MSSBP

Change from baseline in mean sitting systolic blood pressure

Time frame: Baseline, Week 8

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.